Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma

December 9, 2014
Ann S. LaCasce, MD

Ann S. LaCasce, MD, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.

Clinical Pearls

Ann S. LaCasce, MD, assistant professor of medicine, Harvard Medical School, lymphoma program, Dana-Farber Cancer Institute, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.

  • The study analyzed 53 patients with Hodgkin lymphoma who were in first relapse or had primary refractory disease after initial therapy.
  • Patients were treated with brentuximab vedotin in combination with bendamustine.
  • The overall response rate was 96%.
  • 83% of patients achieved a complete remission.
  • Some unexpected infusion-related toxicity was observed.

<<<

Go back to the ASH conference page